8-K: Nektar Therapeutics Enters Clinical Trial Agreement with TrialNet to Evaluate Rezpegaldesleukin in Type 1 Diabetes Patients

Nektar Therapeutics partners with TrialNet to conduct a Phase 2 clinical trial evaluating rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus.

Summary

• Nektar Therapeutics has entered into a clinical trial agreement with TrialNet to evaluate rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus.
• TrialNet will conduct and fund the Phase 2 randomized, double-blind, placebo-controlled clinical trial, which will involve approximately 70 adults and children.
• Nektar will supply rezpegaldesleukin for the study and retain all rights to the program.
• The study aims to investigate the safety and potential efficacy of rezpegaldesleukin, measuring its impact on preserving C-peptide area under the curve over a 12-month period.
• Secondary objectives include assessing pharmacokinetics, pharmacodynamics, HbA1c levels, and patient insulin requirements.
• The study is expected to begin in 2025.

Sentiment

Score: 7

Explanation: The announcement is positive due to the collaboration with TrialNet and the advancement of rezpegaldesleukin into a Phase 2 clinical trial. However, the inherent risks associated with drug development temper the overall sentiment.

Positives

• The collaboration with TrialNet provides external validation and funding for the rezpegaldesleukin program.
• The Phase 2 trial will provide valuable data on the safety and efficacy of rezpegaldesleukin in type 1 diabetes.
• Nektar retains all rights to the rezpegaldesleukin program, maintaining future commercial potential.
• The study's endpoints include clinically relevant measures such as C-peptide levels and insulin requirements.
• The FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Risks

• The success of the clinical trial is uncertain, and rezpegaldesleukin may not demonstrate the desired efficacy or safety profile.
• Regulatory approval is not guaranteed, even with positive clinical trial results.
• The development of rezpegaldesleukin is subject to various risks, including manufacturing challenges and competitive factors.
• The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets.

Future Outlook

Nektar plans to initiate the clinical study in 2025 and continue developing rezpegaldesleukin for autoimmune and inflammatory diseases.

Management Comments

• Jonathan Zalevsky, PhD, Senior Vice President and Chief Research & Development Officer of Nektar, stated that they are looking forward to collaborating with TrialNet to advance rezpegaldesleukin in an important clinical study to evaluate its potential in patients with newly-diagnosed type 1 diabetes.
• Kevan C. Herold, MD, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University, stated that they are excited to explore the potential of rezpegaldesleukin as a novel investigational candidate in people with type 1 diabetes.

Industry Context

This announcement reflects the ongoing efforts to develop novel therapies for type 1 diabetes, an area of significant unmet medical need. Other companies are also developing immunomodulatory therapies for T1D, such as teplizumab, which has already been approved for delaying the onset of stage 3 T1D.

Comparison to Industry Standards

• Rezpegaldesleukin's approach of stimulating regulatory T cells aligns with a broader trend in autoimmune disease research, with companies like Bristol Myers Squibb and Roche also exploring Treg-based therapies.
• The Phase 2 trial design, including the use of C-peptide as a primary endpoint, is consistent with industry standards for T1D clinical trials, as seen in studies of Provention Bio's teplizumab.
• TrialNet's involvement provides credibility and access to a well-established clinical trial network, similar to how companies like Vertex have partnered with academic institutions for diabetes research.

Stakeholder Impact

• Positive for patients with type 1 diabetes, offering a potential new treatment option.
• Positive for Nektar shareholders, demonstrating progress in the company's pipeline.
• Positive for TrialNet, supporting its mission to prevent and stop the progression of type 1 diabetes.

Next Steps

• Initiation of the Phase 2 clinical trial in 2025.
• Continued development of rezpegaldesleukin for other autoimmune and inflammatory diseases.
• Monitoring of clinical trial results and potential regulatory submissions.

Key Dates

Keywords

rezpegaldesleukin, Nektar Therapeutics, TrialNet, type 1 diabetes, clinical trial, autoimmune disease, Treg cells